An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
|Articles|March 4, 2011
- December 2010
- Volume 4
- Issue 6
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk
Advertisement
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.
Articles in this issue
over 15 years ago
Net Guides: Melanomaover 15 years ago
Net Guides: Bone Metastasesover 15 years ago
Yoga for Cancer Careover 15 years ago
FDA Updatesover 15 years ago
The Future of Nursingover 15 years ago
Net Guides: Liver Cancerover 15 years ago
Net Guides: Carcinoma of Unknown Primary Orginover 15 years ago
Tools to Help Patients Navigate Their Treatment Pathover 15 years ago
John Theurer Cancer Center Opens New Comprehensive Facilityalmost 16 years ago
Oncology Community Facing Severe Drug ShortagesAdvertisement
Related to this article
Oncology nurse April Fowler shares her personal stage 4 cancer journey, reflecting on clinical empathy, patient advocacy, and oncology endurance.
Dr. Jason Konner discusses psilocybin, clinician burnout, CIPN prevention, and safety protocols for oncology nurses and care teams in cancer care.
Non-CME PER® Podcast
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
2
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test
3
Reframing Nurse Fatigue as Systemic Safety Risk
4
Oncology Nurse Shares Insights From Her Stage 4 Breast Cancer Journey
5